> Detailanzeige

Libra, Massimo; Talamini, Renato; Crivellari, Diana; Buonadonna, Angela; Freschi, Andrea; Stefanovski, Petar; Berretta, Massimiliano; De Cicco, Marcello; Balestreri, Luca; Merlo, Alberto; Volpe, Rachele; Galligioni, Enzo; Sorio, Roberto

Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution
  • Beteiligte: Libra, Massimo; Talamini, Renato; Crivellari, Diana; Buonadonna, Angela; Freschi, Andrea; Stefanovski, Petar; Berretta, Massimiliano; De Cicco, Marcello; Balestreri, Luca; Merlo, Alberto; Volpe, Rachele; Galligioni, Enzo; Sorio, Roberto
  • Erschienen: SAGE Publications, 2003
  • Erschienen in: Tumori Journal
  • Sprache: Englisch
  • DOI: 10.1177/030089160308900410
  • ISSN: 2038-2529; 0300-8916
  • Schlagwörter: Cancer Research ; Oncology ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Aim and background</jats:title><jats:p> Metastatic renal cell carcinoma is one of the few tumors for which a clear benefit of immunotherapy has been demonstrated. The aim of this study was to evaluate the long-term survival of patients with metastatic renal cell carcinoma, along with response rate and other prognostic and predictive factors. </jats:p></jats:sec><jats:sec><jats:title>Patients and methods</jats:title><jats:p> Between July 1989 and May 1995, 56 patients with metastatic renal cell carcinoma were treated in a single institution with high-dose recombinant interleukin-2 in continuous infusion. Survival was measured by the Kaplan and Meier method. Prognostic factors were assessed by univariate and multivariate analyses of survival (Cox proportional hazard ratio model). </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Of 56 patients, 15 had objective responses (26.8%), 16 stable disease (28.6%), 18 disease progressions (32.1%), and 7 (12.5%) were not valuable for response. Median overall survival was 20 months, and probability of 2- and 5-year survival was 41% and 21%, respectively. At multivariate analysis, the increased risk of death for: performance status ≥2 vs 0 (HR = 6.20), stable disease (HR = 1.87), disease progression (HR = 10.61) vs partial or complete remission, and for hypotension and oliguria toxicity, G3 + G4 vs G1 + G2 (HR = 2.19). </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Our study confirms the activity of IL-2 based immunotherapy in renal cell carcinoma. Moreover, ECOG performance status, clinical response, hypotension and oliguria toxicity resulted as independent survival prognostic factors. </jats:p></jats:sec>